Scientific deep-dive
Muscle Loss: Drug Versus Dieting
Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.
“These drugs make you lose muscle” is the most repeated criticism of GLP-1 medicines, and it is almost never accompanied by the comparison that would make it meaningful. A meta-analysis of 20 randomized trials in 15,782 people supplied it: on incretin drugs, lean mass makes up broadly the same fraction of the weight lost as it does on dieting.[1]
The comparison
| Intervention | Lean share of weight lost |
|---|---|
| Semaglutide | 35.2% (95% CI 31.5–38.9) |
| Liraglutide | 26.8% (95% CI 23.1–30.5) |
| Tirzepatide | 25.4% (95% CI 22.8–28.0) |
| Lifestyle intervention | 26.2% (95% CI 24.1–28.3) |
| Lifestyle plus resistance training | 17.5% (95% CI 14.2–20.8) |
The comparison between incretin drugs as a group and lifestyle intervention returned p=0.42, no significant difference.[1] Losing weight costs lean tissue. It costs about the same proportion whether the weight comes off through a drug or through dieting. The same arithmetic is behind the flatter buttocks people call “Ozempic butt”.
Incretin drugs against lifestyle intervention: no significant difference in how much of the lost weight was lean mass (p=0.42).
The row that actually helps
Adding resistance training brought the lean share down to 17.5%, the most favorable profile in the analysis.[1] It is the only option in the table that cuts the lean share well below dieting’s 26.2%.
That is the practical conclusion, and the exercise trial reached it from a different direction: there the drug alone did nothing for physical fitness, and training did. Two independent lines of evidence point to the same instruction, which is to lift something.
The difference between the drugs is not nothing
The class is not uniform, though. Semaglutide sits at 35.2% and tirzepatide at 25.4%, and those confidence intervals do not overlap.
This analysis cannot say what the gap means. It could reflect the drugs, the speed of loss they produce, the trial populations, or how body composition was measured in each study; heterogeneity across the pooled trials was moderate. The difference is real in the numbers but not yet explained, and it should not decide which one you pick.
What lean mass does and does not tell you
Every figure above is a scan measurement. Whether the person can do more or less is a different question, and one that scans answer badly. In one study muscle volume fell 9.3% while chair-rise and walking speed both edged better (see muscle volume versus muscle function).
So the full picture is three-part: lean mass falls with any weight loss, at a similar proportion drug or diet; resistance training substantially reduces that share; and the mass number alone does not establish that anyone has been harmed. Nor does it mean the drug slowed metabolism; the calorimetry studies are in does Ozempic slow your metabolism.
The pooled figure, across every drug class
A 2026 network meta-analysis pooled 41 randomized trials and 2,906 participants to place every major diabetes and obesity drug against a common reference on fat and lean mass at once.[2] Because every drug is set against the same reference, the numbers can be compared in a way that separate trials read side by side cannot.
| Drug | Fat mass | Lean body mass |
|---|---|---|
| Tirzepatide | −10.70 kg (95% CI −13.42 to −7.99) | −4.40 kg (−7.58 to −1.22) |
| Liraglutide | Moderate reduction | −1.54 kg (−2.55 to −0.52) |
| Semaglutide | Moderate reduction | Not among the significant reductions |
| SGLT2 inhibitors | Modest | Minor losses |
| Metformin, insulin, DPP-4 inhibitors | Neutral or gain | Neutral |
Do the arithmetic on the tirzepatide row: 4.40 kg of lean against 10.70 kg of fat means lean tissue made up roughly 29% of what was lost. That is the best pooled estimate available, and it sits close to what is generally expected of substantial weight loss by any means.
The network also shows the opposite effect. Insulin glargine was associated with fat mass gain, which is the mirror image of what these drugs do and a reminder that “a diabetes drug” is not one thing.
Frequently Asked Questions
References
- 1.Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41877354.
- 2.Rakhsha SS, Shahinfar H, Ebrahimi-Mousavi S, et al. Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42304171.
Compare the sellers
Rankings
Seller reviews
Related research
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.
6 min read
Ozempic Butt: What Large Weight Loss Changes in the Buttocks
No trial has measured buttock shape on semaglutide or tirzepatide. What changes is gluteal fat, some gluteal muscle and skin that does not retract, the same as with any large weight loss. What the DXA and MRI data show, what resistance training keeps, and what surgery can do.
11 min read
Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage
STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.
7 min read
Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started
No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.
9 min read
How Far You Can Walk
Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.
6 min read
Lifestyle Plus the Drug
Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.
5 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
RxSpan MD
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $249/mo
Get started →Collective
From $59/mo + membership
Get started →Embody
From $79/mo
Get started →